{"version":"1.0","provider_name":"Di Renzo Regulatory Affairs","provider_url":"https:\/\/www.direnzo.biz\/it","author_name":"Di Renzo Regulatory Affairs","author_url":"https:\/\/www.direnzo.biz\/it\/author\/admindirenzor\/","title":"Art. 5(3) Referral on Nitrosamines","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"s0PfCOkrPA\"><a href=\"https:\/\/www.direnzo.biz\/it\/nitrosamines-referral\/\">Art. 5(3) Referral on Nitrosamines<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.direnzo.biz\/it\/nitrosamines-referral\/embed\/#?secret=s0PfCOkrPA\" width=\"600\" height=\"338\" title=\"&#8220;Art. 5(3) Referral on Nitrosamines&#8221; &#8212; Di Renzo Regulatory Affairs\" data-secret=\"s0PfCOkrPA\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.direnzo.biz\/it\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/www.direnzo.biz\/it\/wp-content\/uploads\/2022\/01\/nitrosammine.jpg","thumbnail_width":369,"thumbnail_height":300,"description":"Last September EMA opened an&nbsp;Art.5(3) Referral&nbsp;to request the risk assessment of the presence of impurities (nitrosamines) in drugs for human use containing chemically synthesised Active Pharmaceutical Ingredients (APIs). The request originated from the detection \u2013 back in 2018 \u2013 of&nbsp;nitrosamine impurities&nbsp;in some classes of drugs. The impurities found included&nbsp;N-nitrosodimethylamine&nbsp;(NDMA) and&nbsp;N-nitrosodiethylamine&nbsp;(NDEA). As these impurities are considered+ Read More"}